Title: Method of Treating Neurodegenerative Disease
Filed: Oct. 12, 2006
Inventor: David Bumcrot, Alnylam Pharmaceuticals
"Aspects featured in the invention relate to compositions and methods for inhibiting alpha-synuclein gene expression, such as for the treatment of neurodegenerative disorders," the patent's abstract states. "An anti-SNCA agent featured herein that targets the SNCA gene can have been modified to alter distribution in favor of neural cells."